CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40.

Wang R, Graham S, Sun N, McCarthy D, Peng R, Erickson J, Oconnor L, Zhu X, Wurbel M, Dunstan R, et al. CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40. PLoS One. 2020;15(3):e0228221.